Drug Profile
Diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine - Boryung Pharmaceutical
Alternative Names: BR 8002; BVN-002; DTaP-IPV combination vaccineLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 07 Dec 2022 No development reported - Phase-III for Diphtheria (In infants, Prevention) in South Korea (IM) (NCT02458183)
- 07 Dec 2022 No development reported - Phase-III for Pertussis (In infants, Prevention) in South Korea (IM) (NCT02458183)
- 07 Dec 2022 No development reported - Phase-III for Poliomyelitis (In infants, Prevention) in South Korea (IM) (NCT02458183)